Risk factors for venous thromboembolism in patients treated for differentiated thyroid carcinoma

被引:6
|
作者
van der Boom, Trynke [1 ,2 ]
Hesselink, Esther N. Klein [1 ,2 ]
Kooistra, Hilde A. M. [3 ]
Meijer, Karina [3 ]
van der Horst-Schrivers, Anouk N. A. [2 ]
Lefrandt, Joop D. [1 ]
Links, Thera P. [2 ]
机构
[1] Univ Groningen, Univ Med Ctr Groningen, Dept Vasc Med, Groningen, Netherlands
[2] Univ Groningen, Univ Med Ctr Groningen, Dept Endocrinol, Groningen, Netherlands
[3] Univ Groningen, Univ Med Ctr Groningen, Dept Hematol, Groningen, Netherlands
关键词
differentiated thyroid carcinoma; venous thromboembolism; risk factors; CANCER; HYPERTHYROIDISM; SUPPRESSION; THROMBOSIS; THERAPY; DISEASE;
D O I
10.1530/ERC-17-0013
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Although cancer in general is a strong risk factor for developing venous thromboembolism (VTE), the risk factors for venous thromboembolic events in patients with differentiated thyroid carcinoma (DTC) have never been assessed. This is remarkable, as several parts of the treatment comprise a hypercoagulable state that could in subgroups of DTC patients lead to an increased risk of VTE. The aim of this study was to assess which risk factors could cause DTC patients to develop VTE. We performed a nested case-control study, involving cases of DTC patients treated between 1980 and 2014 with confirmed VTE after diagnosis of DTC. Controls were defined as DTC patients without VTE. In all subjects, we collected information about thyroid cancer characteristics, treatment characteristics, traditional risk factors for VTE and additional clinical data, and we performed univariable and multivariable regression analyses. We included 28 cases and 56 controls matched for age at DTC diagnosis, sex and date of DTC diagnosis. In the univariable regression analysis, histology, distant metastases, DTC risk classification, recent surgery and other active malignancy were associated with VTE. In the multivariable analysis, distant metastases (odds ratio 7.9) and recent surgery (odds ratio 6.1) were independently associated with VTE. In conclusion, surgery and presence of distant metastases are independent risk factors for developing VTE in DTC patients. The risk factors identified in this study could be considered when making decisions regarding thromboprophylaxis for patients with thyroid cancer.
引用
收藏
页码:267 / 273
页数:7
相关论文
共 50 条
  • [31] Risk factors in venous thromboembolism
    Martinelli, I
    THROMBOSIS AND HAEMOSTASIS, 2001, 86 (01) : 395 - 403
  • [32] Risk factors for venous thromboembolism
    Lawrence, YR
    ARCHIVES OF INTERNAL MEDICINE, 2004, 164 (21) : 2386 - 2386
  • [33] Risk Factors for Venous Thromboembolism
    Kang, GuanYang
    Zhang, HuiQing
    AMERICAN JOURNAL OF MEDICINE, 2019, 132 (11): : E807 - E807
  • [34] Risk Factors for Venous Thromboembolism
    Goldhaber, Samuel Z.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2010, 56 (01) : 1 - 7
  • [35] Risk factors for venous thromboembolism
    Heit, JA
    CLINICS IN CHEST MEDICINE, 2003, 24 (01) : 1 - +
  • [36] Risk factors for venous thromboembolism
    Le Pecq-Gentil, B
    Sitbon, O
    Abecassis, L
    Virally, J
    Ammar, J
    Mathieu, M
    PRESSE MEDICALE, 1998, 27 (16): : 779 - 785
  • [37] Venous thromboembolism - prevalence and risk factors in chronic venous disease patients
    Musil, Dalibor
    Kaletova, Marketa
    Herman, Jiri
    PHLEBOLOGY, 2017, 32 (02) : 135 - 140
  • [38] Thyroglobulin value in patients surgically treated for differentiated thyroid carcinoma
    Mikac, Gostimir
    Stankovic, Sinisa
    SRPSKI ARHIV ZA CELOKUPNO LEKARSTVO, 2016, 144 (7-8) : 397 - 401
  • [39] Quality of life and associated factors in radio-iodine treated patients with differentiated thyroid carcinoma
    Fallahi, B.
    Ratki, S. Razavi
    Beiki, D.
    Eftekhari, M.
    Fard-Esfahani, A.
    Ardekani, A. Emami
    Namiranian, N.
    Saghari, M.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2013, 40 : S460 - S460
  • [40] Individual risk factors for venous thromboembolism (VTE) in cancer patients treated with targeted therapies (TT)
    Soini, B.
    Caffo, O.
    Ferro, A.
    Ambrosini, G.
    Murgia, V.
    Valduga, F.
    Caldara, A.
    Eccher, C.
    Tumulo, S.
    Galligioni, E.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)